PARP1 and fallopian tube cancer: Another study recruited participants to evaluate the efficacy and safety of avelumab in combination with an ATR inhibitor (M6620) and carboplatin in PARP inhibitor-resistant, recurrent, platinum-sensitive ovarian, primary peritoneal, or fallopian tube cancer.